COLLEGIUM PHARMACEUTICAL, INC Research And Development Expense

• This data is from COLLEGIUM PHARMACEUTICAL, INC's annual report (Form 10-K), filed with the SEC on February 27, 2025.
• XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2014: $3.27 million | Q2 2014: $3.57 million | Q3 2014: $5.82 million | Q4 2014: $2.31 million | Q1 2015: $1.45 million | Q2 2015: $1.64 million | Q3 2015: $3.36 million | Q4 2015: $1.53 million | Q1 2016: $4.06 million | Q2 2016: $4.30 million | Q3 2016: $3.25 million | Q4 2016: $3.33 million | Q1 2017: $2.13 million | Q2 2017: $2.18 million | Q3 2017: $2.07 million | Q4 2017: $2.19 million | Q1 2018: $2.27 million | Q2 2018: $2.24 million | Q3 2018: $1.91 million | Q4 2018: $2.25 million | Q1 2019: $2.99 million | Q2 2019: $2.46 million | Q3 2019: $2.49 million | Q4 2019: $2.40 million | Q1 2020: $2.67 million | Q2 2020: $2.49 million | Q3 2020: $2.14 million | Q4 2020: $2.47 million | Q1 2021: $2.93 million | Q2 2021: $3.46 million | Q3 2021: $1.45 million | Q4 2021: $1.61 million | Q1 2022: $3.98 million | Q2 2022: $0.00.
• Over the full 12 years of available data (2013 to 2024), COLLEGIUM PHARMACEUTICAL, INC's Research And Development Expense has declined by 100.0%.
• Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $0.00 | Fiscal year 2022: $3.98 million | Fiscal year 2021: $9.45 million | Fiscal year 2020: $9.77 million | Fiscal year 2019: $10.34 million | Fiscal year 2018: $8.66 million | Fiscal year 2017: $8.57 million | Fiscal year 2016: $14.95 million | Fiscal year 2015: $7.98 million | Fiscal year 2014: $14.96 million | Fiscal year 2013: $14.16 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026